Key findings from the 2007 European Society of Cardiology Congress

Reviews in Cardiovascular Medicine

Volumn 8, Issue 4, 2007, Pages 220-227

  Lepor, Norman E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abciximab; Angina; Bare metal stents; Diabetes; Drug eluting stents; Heart failure; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ALISKIREN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; INDAPAMIDE; PERINDOPRIL; PLACEBO; RANOLAZINE; RETEPLASE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTERY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CORONARY STENT; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOADING DRUG DOSE; MEDICAL SOCIETY; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 38349170976     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Di Mario C. Randomised evaluation of routine transfer for urgent PCI or local management for patients admitted with STEMI to centres without PCI facilities initially treated with reteplase, heparin and abciximab (CARESS in AMI). Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
2. Ellis S. Final results of the FINESSE (Facilitated INtervention With Enhanced Reperfusion Speed To Stop Events) trial: evaluation of abciximab + half-dose reteplase, abciximab alone, or placebo for facilitation of primary PCI for ST elevation MI. Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
3. MacMahon S. ADVANCE - A factorial randomised trial of blood pressure lowering and intensive glucose control for the prevention of vascular disease among high risk individuals with type 2 diabetes: results of the blood pressure intervention. Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
4. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet. 2007;370:829-840.
5. McMurray J. Aliskiren Observations of Heart Failure Treatment (ALOFT). Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
6. Widimsky P. Optimal pre-PCI clopidogrel loading: 600 mg before every coronary angiography vs 600 mg in cath-lab only for PCI patients (PRAGUE-8). Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
7. Baumgartner I. ReoPro and peripheral arterial intervention to improve clinical outcome in patients with peripheral arterial disease trial (RIO-Trial). Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
8. Montalescot G. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. STEEPLE one year follow-up. Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
9. Seyfarth M. One-year clinical outcomes in the ISAR-REACT 2 trial, a randomised comparison of abciximab versus placebo in patients with non-ST segment elevation acute coronary syndromes undergoing PCI after pretreatment with clopidogrel. Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
10. White H. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: ACUITY trial one year results. Paper presented at: European Society of Cardiology Congress; September 2007; Vienna, Austria.
11. Scirica BM, Morrow DA, Hanoch H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine For Less Ischemia In Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation. 2007;116:1647-1652.